| abstract |
The present invention relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof, and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for use in the treatment of various CNSs Use in diseases where an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO) or 3',5'-cyclic guanosine monophosphate (cGMP) or both, or an upregulation of the NO pathway is desirable. |